The General Assembly of the United Nations issued a note about an upcoming event to occur this week at the UN Headquarters in New York.
On Sept. 21, the president of the UN General Assembly plans to convene a high-level meeting on antimicrobial resistance for the first time.
According to the post, the primary objective of the meeting is to summon and maintain strong national, regional and international political commitment in addressing antimicrobial resistance comprehensively and multi-sectorally, and to increase and improve awareness of antimicrobial resistance.
The meeting emphasizes the important role and the responsibilities of governments, as well as the role of relevant inter-governmental organizations, particularly the World Health Organization within its mandate and in coordination with FAO and o IE, as appropriate, in responding to the challenges of antimicrobial resistance, and the essential need for multi-sectorial and cross-sectorial efforts and engagement of all relevant sectors of society, -such as human and veterinary medicine, agriculture, finance, environment and consumers- to generate an effective response, including towards a one-health approach.
It further recalls the World Health Assembly Resolution WHA 68.7 entitled “Global Action Plan on antimicrobial resistance” which reflects a global consensus that antimicrobial resistance poses a significant public health challenge, and emphasizing the paramount significance of achieving the five strategic objectives of the WHA Global Action Plan, which include:
- Improve awareness and understanding of antimicrobial resistance through effective communication, education and training
- Strengthen the knowledge and evidence base through surveillance and research
- Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures
- Optimize the use of antimicrobial medicines in human and animal health
- Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions